| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
| filingDate |
2010-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2015-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101489045-B1 |
| titleOfInvention |
Combinations of a pi3k inhibitor and a mek inhibitor |
| abstract |
The present invention relates to a method of treating a patient having a locally advanced or metastatic solid tumor with a combination of the phosphatidylinositol 3 kinase (PI3K) inhibitor and mitogen activated protein kinase (MEK) inhibitor described herein. |
| priorityDate |
2009-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |